Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics
Jennifer M. Speth, Loka R. Penke, Joseph D. Bazzill, Kyung Soo Park, Rafael Gil de Rubio, Daniel J. Schneider, Hideyasu Ouchi, James J. Moon, Venkateshwar G. Keshamouni, Rachel L. Zemans, Vibha N. Lama, Douglas A. Arenberg, Marc Peters-Golden
Jennifer M. Speth, Loka R. Penke, Joseph D. Bazzill, Kyung Soo Park, Rafael Gil de Rubio, Daniel J. Schneider, Hideyasu Ouchi, James J. Moon, Venkateshwar G. Keshamouni, Rachel L. Zemans, Vibha N. Lama, Douglas A. Arenberg, Marc Peters-Golden
View: Text | PDF
Research Article Immunology Oncology

Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics

  • Text
  • PDF
Abstract

Lung cancer remains the leading cause of cancer-related death in the United States. Although the alveolar macrophage (AM) comprises the major resident immune cell in the lung, few studies have investigated its role in lung cancer development. We recently discovered a potentially novel mechanism wherein AMs regulate STAT-induced inflammatory responses in neighboring epithelial cells (ECs) via secretion and delivery of suppressors of cytokine signaling 3 (SOCS3) within extracellular vesicles (EVs). Here, we explored the impact of SOCS3 transfer on EC tumorigenesis and the integrity of AM SOCS3 secretion during development of lung cancer. AM-derived EVs containing SOCS3 inhibited STAT3 activation as well as proliferation and survival of lung adenocarcinoma cells. Levels of secreted SOCS3 were diminished in lungs of patients with non–small cell lung cancer and in a mouse model of lung cancer, and the impaired ability of murine AMs to secrete SOCS3 within EVs preceded the development of lung tumors. Loss of this homeostatic brake on tumorigenesis prompted our effort to “rescue” it. Provision of recombinant SOCS3 loaded within synthetic liposomes inhibited proliferation and survival of lung adenocarcinoma cells in vitro as well as malignant transformation of normal ECs. Intratumoral injection of SOCS3 liposomes attenuated tumor growth in a lung cancer xenograft model. This work identifies AM-derived vesicular SOCS3 as an endogenous antitumor mechanism that is disrupted within the tumor microenvironment and whose rescue by synthetic liposomes can be leveraged as a potential therapeutic strategy for lung cancer.

Authors

Jennifer M. Speth, Loka R. Penke, Joseph D. Bazzill, Kyung Soo Park, Rafael Gil de Rubio, Daniel J. Schneider, Hideyasu Ouchi, James J. Moon, Venkateshwar G. Keshamouni, Rachel L. Zemans, Vibha N. Lama, Douglas A. Arenberg, Marc Peters-Golden

×

Figure 5

SOCS3 liposomes inhibit lung tumor cell function and epithelial cell transformation.

Options: View larger image (or click on image) Download as PowerPoint
SOCS3 liposomes inhibit lung tumor cell function and epithelial cell tra...
(A) A549 cells were incubated with liposomes containing 10 ng SOCS3 or an equal volume of liposomes containing PBS alone (empty) for 72 h and analyzed by CyQuant cell proliferation assay measuring total cellular DNA (n = 3 separate experiments). (B) One thousand A549 cells were plated per well of a 96-well tissue culture plate and were incubated with empty or SOCS3 liposomes for 72 h. Cellular confluence was measured using an IncuCyte Live Cell Analysis system. Data points represent the mean of quadruplicate measurements of confluency, expressed as AU per well, and are representative of triplicate wells per condition. (C) A549 cells were treated with empty or SOCS3 liposomes for 24 h and analyzed for FoxM1 mRNA expression by qPCR (n = 3 separate experiments). (D) Representative micrographs of caspase-3/7–positive cells after liposome treatment. Concurrent with the confluence assay in B, A549 cells were incubated with IncuCyte caspase-3/7 apoptosis assay reagent and empty or SOCS3 liposomes. Fluorescence micrographs are representative of 3 triplicate wells per treatment. Scale bar: 100 μm. (E) A549 cells were treated with empty or SOCS3 liposomes or FasL (as a positive control) for 24 h, and annexin V+ cells determined via flow cytometry (n = 4–5 replicate samples). (F) A549 cells were treated with empty or SOCS3 liposomes for 24 h and analyzed for relative FasR mRNA expression by qPCR (n = 4 separate experiments). (G) A549 cells were treated with FasL, empty liposomes, or SOCS3 liposomes for 24 h, with or without the pan-caspase inhibitor Z-VAD-FMK (Z), and cell proliferation was determined by CyQuant assay (n = 5–14 replicates from 3 separate experiments). (H) Top: Schematic depiction of CSE transformation protocol for WT or G12V-RLE cells. A total of 0.5 × 106 RLE-6TN cells were incubated with either WT or G12V retrovirus for 24 h. Cells were washed and selected with puromycin for an additional 48–72 h. Surviving cells were passaged an additional 2 times before use in experiments. For CSE transformation, cells were plated at a concentration of 10,000 cells/well of a 6-well tissue culture dish and treated with 3% CSE, along with empty or SOCS3 liposomes, for 1 h daily for 7 consecutive days. They were then cultured in equal numbers in a soft agar colony assay for an additional 7 days before colonies were enumerated. Bottom left: Representative micrographs of CSE-treated WT or G12V RLEs within a soft agar colony assay. Photographs were taken at 40× magnification. Scale bar: 1000 μm. Bottom right: Data represents mean colony counts from 7 separate 40× fields per treatment from 3 separate experiments. Student’s 2-tailed t test was used for comparison of 2 groups (A, C, F, and H), or 1-way ANOVA with Bonferroni’s post hoc analysis was used for multiple comparisons (E and G); *P < 0.05 or #P < 0.05 represents comparison to control or empty liposomes, respectively.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts